Deuremidevir hydrobromide - Vigonvita Life Sciences
Alternative Names: JT-001 - Junshi Biosciences; Mindevir; MINDEWEI®; VV-116Latest Information Update: 04 Jun 2024
At a glance
- Originator Vigonvita Life Sciences
- Developer Shanghai Junshi Biosciences; Vigonvita Life Sciences
- Class Adenine nucleotides; Amines; Antivirals; Esters; Furans; Nitriles; Organic deuterium compounds; Pyrroles; Small molecules; Triazines
- Mechanism of Action RNA replicase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Registered COVID 2019 infections
- Phase II Respiratory syncytial virus infections
Most Recent Events
- 06 May 2024 Vigonvita Life Sciences completes a phase I trial for Respiratory syncytial virus infections (In volunteers) in China (PO, suspension) (NCT06328400)
- 27 Mar 2024 Vigonvita Life Sciences initiates a phase I trial for Respiratory syncytial virus infections (In volunteers) in China (PO, suspension) (NCT06328400)
- 20 Mar 2024 Vigonvita Life Sciences plans a phase I trial for Respiratory syncytial virus infections (In volunteers) in China (PO, suspension) in March 2024 (NCT06328400)